ROCHESTER, N.Y., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced its CEO, Maurice Zauderer, Ph.D., will participate in a panel titled, “ImmunoOncology in Solid Tumors: What’s After PD1s?” and meet with investors at the BTIG Healthcare Conference on October 25, 2018.
The conference will be held from 8AM to 5PM at the Langham Hotel, 400 Fifth Avenue in New York City. The panel will be held from 3:30PM to 4:20PM. Investors interested in one-on-one meetings should contact the conference organizers or Michael Rice from LifeSci Advisors at mrice@lifesciadvisors.com.
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York.
Investor Contact
Michael Rice
LifeSci Advisors, LLC
Phone: (646) 597-6979
E-mail: mrice@lifesciadvisors.com
Media Contact
Jules Abraham
JQA Partners, Inc.
Phone: (917) 885-7378
E-mail: jabraham@jqapartners.com